Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.